Shares of Urogen Pharma (NASDAQ:URGN) have been given a consensus broker rating score of 1.25 (Strong Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation and three have issued a strong buy recommendation on the company.

Brokerages have set a 1-year consensus price target of $28.00 for the company and are expecting that the company will post ($0.05) EPS for the current quarter, according to Zacks. Zacks has also assigned Urogen Pharma an industry rank of 110 out of 265 based on the ratings given to related companies.

URGN has been the subject of a number of analyst reports. Zacks Investment Research raised Urogen Pharma from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a report on Wednesday, August 2nd. Oppenheimer Holdings, Inc. set a $32.00 price target on Urogen Pharma and gave the stock a “buy” rating in a report on Monday. Cowen and Company started coverage on Urogen Pharma in a report on Tuesday, May 30th. They set an “outperform” rating for the company. Jefferies Group LLC started coverage on Urogen Pharma in a report on Tuesday, May 30th. They set a “buy” rating and a $27.00 target price for the company. Finally, Raymond James Financial, Inc. started coverage on Urogen Pharma in a report on Tuesday, May 30th. They set an “outperform” rating and a $25.00 target price for the company.

Shares of Urogen Pharma (URGN) traded up 1.59% during mid-day trading on Thursday, reaching $17.90. The company had a trading volume of 4,397 shares. The stock has a 50 day moving average of $17.96 and a 200-day moving average of $17.59. Urogen Pharma has a 52 week low of $13.01 and a 52 week high of $20.02. The company’s market capitalization is $41.26 million.

COPYRIGHT VIOLATION WARNING: “Brokerages Anticipate Urogen Pharma (URGN) to Post ($0.05) EPS” was posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/17/brokerages-anticipate-urogen-pharma-urgn-to-post-0-05-eps.html.

Several institutional investors have recently made changes to their positions in URGN. Alps Advisors Inc. purchased a new position in shares of Urogen Pharma during the second quarter worth approximately $195,000. LLBH Private Wealth Management LLC purchased a new position in shares of Urogen Pharma during the second quarter worth approximately $695,000. Spark Investment Management LLC purchased a new position in shares of Urogen Pharma during the second quarter worth approximately $856,000. Menora Mivtachim Holdings LTD. purchased a new position in shares of Urogen Pharma during the second quarter worth approximately $2,331,000. Finally, Wildcat Capital Management LLC purchased a new position in shares of Urogen Pharma during the second quarter worth approximately $2,439,000. 3.59% of the stock is owned by institutional investors and hedge funds.

About Urogen Pharma

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Get a free copy of the Zacks research report on Urogen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.